Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Refractory or Relapsed Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Lethal Congenital Contracture Syndrome 2 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Breast Cancer 1

Interventions

Carboplatin 11atezolizumab 10Etoposide 9Topotecan 6PM 01183 6durvalumab 5Specimen Handling 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Irinotecan 2Injections 2Drug Therapy 2Cisplatin 2Biopsy 2AMG 757 2trastuzumab deruxtecan 1toripalimab 1olaparib 1lenvatinib 1fludarabine 1enzalutamide 1cabozantinib 1berzosertib 1avelumab 1arginine decarboxylase 1amrubicin 1Vaccines 1Taxes 1Sodium Chloride 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Itraconazole × 30 days × Clear all
NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Pfizer

Phase 1 Recruiting
453 enrolled
LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡